Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (Weighted Average) (2016 - 2025)

Syndax Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 11 years, most recently at $86.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $86.6 million for Q4 2025, up 1.17% from a year ago — trailing twelve months through Dec 2025 was $86.6 million (up 1.17% YoY), and the annual figure for FY2025 was $86.6 million, up 1.17%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $86.6 million at Syndax Pharmaceuticals, roughly flat from $86.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for SNDX hit a ceiling of $86.6 million in Q4 2025 and a floor of $51.5 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $69.7 million (2023), compared with a mean of $70.7 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 50.02% in 2021 and later grew 1.13% in 2025.
  • Syndax Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $52.1 million in 2021, then increased by 16.7% to $60.8 million in 2022, then increased by 15.82% to $70.4 million in 2023, then grew by 21.67% to $85.6 million in 2024, then increased by 1.17% to $86.6 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $86.6 million (Q4 2025), $86.5 million (Q3 2025), and $86.3 million (Q2 2025) per Business Quant data.